Document:

LICENSE AGREEMENT

PURCHASE AGREEMENT

BETWEEN ANTHOS HOLDINGS LLC

 AND 

NEOVAX INCORPORATED

Whereas  ANTHOS HOLDINGS LLC, owns technologies related to the development and production of  recombinant DNA vaccine/s for avian influenza viruses.

Whereas NEOVAX INC , seeks to purchase  these technologies with the purpose to commercialize these technologies

The Parties do hereby enter into the following Agreement:

PART I – PARTIES

1.

Parties

1.1

For purposes of this Agreement, the term “Parties” shall collectively refer to ANTHOS HOLDINGS LLC, a Colorado limited liability company (hereinafter “ANTHOS”), located at 11880 Antler Trail, Littleton CO 80127, and NEOVAX INC. located at 6812 Idylwild Ct. Boulder CO 80301

PART II - TERMS AND DEFINITIONS

2.

Definitions

2.1

The Parties have negotiated the terms of this Agreement hereto and the language used in this Agreement shall be deemed to be the language chosen by the Parties hereto to express their mutual intent.  This Agreement shall be construed without regard to any presumption or rule requiring construction against the Party causing such instrument or any portion thereof to be drafted, or in favor of the Party receiving a particular benefit under this Agreement.  No rule of strict construction will be applied against any person.

2.2

The term “Confidential Information” shall mean any confidential idea, communication, prototype or work product, expressed or demonstrated in any manner, without requirement that it be reduced to a fixed medium or tangible form, in which someone may hold ownership.  The term “Confidential Information” shall not apply to the following:

A.

Information that was in the public domain at the time it was disclosed or falls within the public domain through no breach of this Agreement;

B.

Information that was known to the receiving Party at the time of disclosure without obligation of confidentiality;

C.

Information that was made known to the receiving Party from a source other than the disclosing Party without any breach of confidence or violation of law.

2.3

Wherever the context may require, any pronouns used in this Agreement shall include the corresponding masculine, feminine, or neuter forms, and the singular form of nouns or pronouns shall include the plural and vice versa.

2.4

Captions of the paragraphs and subparagraphs of this Agreement are for convenience and reference only, and the words contained therein shall in no way be held to explain, modify, amplify or aid in the interpretation or construction of the provisions of this Agree­ment.

PART III - OBLIGATIONS OF ANTHOS

3.

Grant of Ownership

3.1

ANTHOS hereby grants to NEOVAX INC the exclusive and perpetual ownership of  technologies related to the development and commercialization of a recombinant DNA vaccine for avian influenza virus  subject to no conditions and limitations:

           Warranties and Representations

3.2

ANTHOS WARRANTS THAT TO THE BEST OF ITS KNOWLEDGE THERE ARE NO OTHER CLAIMANTS TO THE OWNERSHIP OF ITS AVIAN INFLUENZA VACCINE TECHNOLOGY.

3.3

ANTHOS WARRANTS THAT TO THE BEST OF ITS KNOWLEDGE THE PRODUCTION AND USE OF THE AVIAN INFLUENZA VACCINE TECHNOLOGY WILL NOT INFRINGE UPON THE RIGHTS OF ANY THIRD PARTY.

4.

Enforcement of Intellectual Property Rights

4.1

NEOVAX INC. shall take any action, as it shall deem appropriate in its sole discretion to apply for and maintain patent, copyright, trade secret and/or trademark ownership rights in the Avian Influenza Vaccine technology.

PART IV - DUTIES AND OBLIGATIONS OF NEOVAX INC

5.

Fees,  Payments

5.1

NEOVAX shall make to ANTHOS a payment of 30,000,000 equal to $10,000,000 of its unrestricted common shares. 

PART V - MUTUAL DUTIES AND OBLIGATIONS OF PARTIES

6.

Compliance with Laws

6.1

Each Party shall fully comply with all local, state, and country laws and regulations, which may be applicable to the performance of this Agreement.

7.

Confidential Information

7.1

Either Party or their representatives may disclose Confidential Information to the other Party.  Prior to disclosure, the Confidential Information shall be clearly designated in writing as confidential.

7.2

Each Party shall retain ownership in their respective Confidential Information disclosed under this Agreement, except for that Confidential Information specifically transferred by performance of this Agreement.

7.3

Each Party may use or disclose the other’s Confidential Information only to the extent specifically authorized by this Agreement or as necessary to perform this Agreement and only after obtaining the written prior approval of the other Party.  The right of use and disclosure shall be subject to the limitations herein.

7.4

Each Party shall treat the other’s Confidential Information as a trade secret of the other Party.  Each Party shall actively seek to maintain the secrecy and prevent disclosure of the other Party’s Confidential Information.

7.5

In the event that disclosure of Confidential Information is necessary to the performance of this Agreement, the disclosing Party shall obtain a written agreement from any third-Party recipient of the Confidential Information, which complies with the terms and conditions stated herein regarding use and disclosure of the Confidential Information.

7.6

The obligations listed in this section of the Agreement shall continue for the term of this Agreement and a period of five (5) years thereafter.

7.7

In the event that a dispute arises regarding the confidentiality of information, the information disclosed shall be treated as Confidential Information until such time as a determination is made under the dispute provisions of this Agreement.

8.

Transfer of Obligations

8.1

Subject to the limitations regarding assignment, this Agreement shall be binding on, and shall inure to the benefit of the Parties, their respective legal heirs, representatives, successors and assigns.

9.

Interpretation

9.1

This Agreement supersedes and replaces in its entirety any prior agreements between the Parties.

10.

Survival of Representations and Warranties

10.1

All representations, warranties, covenants and agreements of the Parties contained in this Agreement or in any instrument, certifi­cate, document or other writing provided for in this Agreement or the Schedules hereto, shall remain in full force and shall be deemed renewed by each of them after signing of this Agreement.

11.

Indemnification

11.1

Each Party hereto hereby agrees to indemnify, defend and hold harmless the other Party/Parties and its/their respec­tive officers, directors, shareholders, agents, representatives, em­ployees, affiliates, executors, administrators, successors and assigns (herein­after collectively referred to as the “Indemnitees”) from and against any and all claims, demands, losses, costs, expenses, obligations, liabilities, actions, suits, damages, diminution in value and deficien­cies, including, without limitation, interest and penalties, attorneys’ fees, costs of investigation and all amounts paid in settle­ment of any claim, action or suit (hereinafter collectively referred to as the “Claims”) which may be asserted against the Indemnitees, or any of them, or which any of the Indemnitees may incur or suffer which arise out of, result from or relate to the breach of any repre­sentation or warranty or the nonfulfillment of any covenant or agree­ment of any other Party contained in this Agreement, the Schedules hereto or in any documents or writing to be delivered after signing of this Agreement.

12.

Remedies Not Exclusive

12.1

No remedy conferred by any of the specific provisions of this Agreement is intended to be exclusive of any other remedy and each and every remedy shall be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law or in equity or by statute or otherwise. No remedy shall be deemed to be a limitation on the amount or measure of damages resulting from any breach of this Agreement. The election of any one or more remedies shall not constitute a waiver of the right to pursue other available remedies.  

13.

Waiver by Accepting Varied Performance

13.1

No waiver of any provision or consent to any action shall constitute a waiver of any other provision or consent to any other action, whether or not similar.  No waiver or consent shall constitute a continuing waiver or consent or commit a Party to provide a waiver in the future except to the extent specifically set forth in writing.  Any waiver given by a Party shall be null and void if the Party requesting such waiver has not provided a full and complete disclosure of all material facts relevant to the waiver requested.

14.

Force Majeure

14.1

Neither Party shall be responsible for any delay in its performance of any of its obligations under this Agreement due to circumstances beyond its reasonable control. 

15.

Governing Law

15.1

All matters concerning the execution and authori­zation of this Agreement and related documents and all other matters relating to this Agreement and related documents (including, without limitation, the enforcement, interpretation and construction of this Agreement and related documents) shall be governed by the laws of the State of Colorado, irrespective of such state’s choice-of-law principles and of the United States.

16.

Scope of Agreement

16.1

This Agreement and the Schedule hereto, as well as agreements and other documents referred to in this Agreement constitute the entire agreement between the Parties with regard to the subject matter hereof and thereof.  This Agreement supersedes all previous agreements between or among the Parties.  There are no agreements, representations, or warranties between or among the Parties other than those set forth in this Agreement or the documents and agreements referred to in this Agreement.  Each Party has been independently advised of the tax and accounting consequences of this transaction, has relied on the advice of its own counsel and accountants, and has not relied in any way upon any representations, warranties or advice in these matters from the other Parties.  No provision in this Agreement shall be construed to constitute any Party (or the officers, directors or employees thereof) the agent or general partner of any other Party or confer upon them the right to contract in the name of or bind such other Party in any way.  This Agreement may not be modified except by an agreement in writing signed by the Party against whom the enforcement of any waiver, change, modifi­cation or discharge is sought.  This Agreement shall survive the execution of any instruments executed pursuant to the terms hereof.  

17.

Severability

17.1

If any term or provision of this Agreement is determined to be illegal, unenforceable, or invalid in whole or in part for any reason, such illegal, unenforceable, or invalid provisions or part thereof shall be stricken from this Agreement, and such provision shall not affect the legality, enforceability, or validity of the remainder of this Agreement.  If any provision or part thereof of this Agreement is stricken in accordance with the provisions of this paragraph, then this stricken provision shall be replaced, to the extent possible, with a legal, enforceable, and valid provision that is as similar in tenor to the stricken provision as is legally possible.

17.2

If either Party in good faith determines that the finding of illegality or unenforceability adversely affects the material consideration for its performance under this Agreement, then such Party may, at its option, by giving written notice to the other, terminate the Agreement. In such event the Parties shall take such reasonable action to restore each Party to the position it was in prior to the making of this Agreement.

18.

Notices

18.1

All notices, requests, demands, and other communications required to or permitted to be given under this Agreement shall be in writing and shall be conclusively deemed to have been duly given

A.

When hand delivered to the other Party; or 

B.

When received when sent by facsimile or email at the address and number set forth below (provided, however, that notices given by facsimile or email shall not be effective unless either

(1)

A duplicate copy of such facsimile notice is promptly given by depositing same in a United States post office with first-class postage prepaid and addressed to the Parties as set forth below, or

(2)

The receiving Party delivers a written confirmation of receipt for such notice either by facsimile or email or any other method permitted under this paragraph.

0.1

Any notice given by facsimile or email shall be deemed received

A.

On the next business day if such notice is received after 5:00 p.m. (recipient’s time) or on a nonbusiness day; or

B.

Three (3) business days after the same have been deposited in a United States post office with first class or certified mail return receipt requested postage prepaid and addressed to the Parties as set forth below; or

C.

The next business day after same have been deposited with a national overnight delivery service reasonably approved by the Parties (Federal Express, UPS and DHL WorldWide Express being deemed approved by the Parties), postage prepaid, addressed to the Parties as set forth below with next-business-day delivery guaranteed, provided that the sending Party receives a confirmation of delivery from the delivery service provider.

If to NEOVAX INC.:

Jose Sandoval, President

NEOVAX INC.

Boulder, CO 80301

Phone:(303)717-0709

 

If  to ANTHOS  HOLDINGS LLC:

Patrick J Rundle, Managing  Director

ANTHOS HOLDINGS LLC

Littelton, CO 80127

Phone: (303) 674-2145

Fax: (303) 674-2113

          Each Party shall make an ordinary, good faith effort to ensure that it will accept or receive notices that are given in accordance with this paragraph, and that any person to be given notice actually receives such notice.  A Party may change or supplement the addresses given above, or designate additional addresses, for purposes of this paragraph by giving the other Party written notice of the new address in the manner set forth above.

1.

Fees and Expenses.

1.1

The Parties shall each pay their own expenses, including, but not limited to, legal and accounting expenses incident to the execution of this Agreement and the consummation of the transactions contemplated hereby whether or not such transactions shall be consummated.

2.

Incorporation by Reference, Counterparts, and Facsimile Copies. 

2.1

This Agreement may be executed by the Parties in several counterparts, each of which shall be deemed to be an original copy, but all of which taken together shall constitute one and the same instrument.  

2.2

This Agreement shall not be effective until the execution and delivery between each of the Parties of at least one set of counterparts.  The Parties authorize each other to detach and combine original signature pages and consolidate them into a single identical original.  Any one of such completely executed counterparts shall be sufficient proof of this Agreement.  

2.3

The Schedule annexed to this Agreement shall constitute a part of this Agreement. 

2.4

Words or phrases in the Schedule that have been defined, as indicated by initial capital letters, shall have the same meaning as the same initially capitalized words or phrases have in this Agreement and vice versa.

2.5

The Parties agree that a facsimile of an executed copy of this Agreement shall be treated as if it were an original.

2.6

In the event that the Parties do not enter into all of the activities described within the Schedules, this Agreement shall be in full force and effect.

3.

Agreement to Perform Necessary Acts

3.1

The Parties shall at their own cost and expense execute and deliver such further documents and instruments and shall take such other actions as may be reasonably required or appropriate to carry out the intent and purposes of this Agreement.

4.

Time of Essence

4.1

Time is of the essence in respect to all provisions of this Agreement in which a definite time for performance is specified; provided, however, that the foregoing shall not be construed to limit or deprive a Party of the benefits of any grace or use period provided for in this Agreement.

5.

Representation on Authority of Parties

5.1

Each person signing this Agreement represents and warrants that he or she is duly authorized and has legal capacity to execute and deliver this Agreement.  

5.2

Each Party represents and warrants to the other that the execution and delivery of the Agreement and the performance of such Party’s obligations hereunder have been duly authorized and that the Agreement is a valid and legal agreement binding on such Party and enforceable in accordance with its terms.

PART VI – TERM

6.

Term and Termination

6.1

This Agreement will commence on the date set forth on the signature page below. 

PART VII - DISPUTE AND BREACH OF AGREEMENT

7.

Breach of Agreement 

7.1

In the event either Party should fail to perform any of its obligations under this Agreement, the non-defaulting Party may give written notice of breach to the defaulting Party.  The defaulting Party shall have twenty (20) days from receipt of written notice to cure the default.  If the default is not cured within the time period, the non-defaulting Party shall be entitled to any and all remedies provided under this Agreement or by the laws of the State of Colorado.

8.

Mediation

8.1

If a dispute arises out of or relates to this Agreement, or the breach thereof, and if said dispute cannot be settled through negotiation, the Parties agree first to try in good faith to settle the dispute by mediation under the Commercial Mediation Rules of the American Arbitration Association before resorting to arbitration.  The site of the mediation shall be in Denver, Colorado

9.

Arbitration

9.1

Any claim or controversy arising out of or relating to the performance of this Agreement, which has not been settled by mediation, shall be settled by arbitration in Denver, Colorado, in accordance with the Commercial Arbitra­tion Rules of the American Arbitration Association, as herein amended.

9.2

The arbitration panel shall be comprised of three business people with experience in the development and licensing of audio technologies.  Judgment upon the arbitration award rendered by the arbitrators may be entered in any Court having jurisdiction thereof. 

9.3

Discovery shall be permitted to enable the Parties to prepare for the arbitration hearing.  The arbitrators shall settle all disputes regarding discovery.

9.4

Either Party may apply to any court having jurisdiction hereof and seek injunctive relief so as to maintain the status quo of the Parties until such time as the arbitration award is rendered or the controversy otherwise resolved.

10.

Attorney Fees

10.1

If either Party to this Agreement shall bring any action, suit, counterclaim, appeal, arbitration, or mediation for any relief against the other, declaratory or otherwise, to enforce the terms hereof or to declare rights hereunder (collectively, an Action), the losing Party shall pay to the prevailing Party a reasonable sum for attorneys’ fees and costs (at the prevailing Party’s attorneys’ then-prevailing rates as increased from time to time by the giving of advance written notice by such counsel to such Party) incurred in bringing and prosecuting such Action and/or enforcing any judgment, order, ruling, or award (collectively, a Decision) granted therein, all of which shall be deemed to have accrued on the commencement of such Action and shall be paid whether or not such Action is prosecuted to a Decision.

10.2

Any Decision entered in such Action shall contain a specific provision providing for the recovery of attorneys’ fees and costs incurred in enforcing such Decision.  

10.3

The court or arbitrator may fix the amount of reasonable attorneys’ fees and costs on the request of either Party.  For the purposes of this Section 39, attorneys’ fees shall include, without limitation, fees incurred in the following: (1) post judgment motions and collection actions; (2) contempt proceedings; (3) garnishment, levy, and debtor and third Party examinations; (4) discovery; and (5) bankruptcy litigation.

10.4

For purposes of this Section 39, “Prevailing Party” shall mean, without limitation, a Party who agrees to dismiss an Action on the other Party’s payment of the sums allegedly due or performance of the covenants allegedly breached, or who obtains substantially the relief sought by it.

11.

Consent to Jurisdiction and Forum Selection

11.1

The Parties hereto agree that all actions or proceedings arising in connection with this Agreement shall be tried and litigated exclusively in the State courts located in the State of Colorado.

11.2

The aforementioned choice of venue is intended by the Parties to be mandatory and not permissive in nature, thereby precluding the possibility of litigation between the Parties with respect to or arising out of this Agreement in any jurisdiction other than that specified in this paragraph.  Each Party hereby waives any right it may have to assert the doctrine of forum non conveniens or similar doctrine or to object to venue with respect to any proceeding brought in accordance with this paragraph, and stipulates that the State courts located in the State of Colorado.

11.3

The State of Colorado shall have in personam jurisdiction and venue over each of them for the purpose of litigating any dispute, controversy, or proceeding arising out of or related to this Agreement.  Each Party hereby authorizes and accepts service of process sufficient for personal jurisdiction in any action against it as contemplated by this paragraph by registered or certified mail, return receipt requested, postage prepaid, to its address for the giving of notices set forth in this Agreement, or in the manner set forth in paragraph 18 of this Agreement for the giving of notice.  Any final judgment rendered against a Party in any action or proceeding shall be conclusive as to the subject of such final judgment and may be enforced in other jurisdictions in any manner provided by law.

THE PARTIES HEREBY ACCEPT THIS AGREEMENT AND AGREE TO BE BOUND BY ITS TERMS AND CONDITIONS THIS __1__ DAY OF _OCTOBER,  2006.

ANTHOS HOLDINGS, LLC 

Signature of Representative, Managing Director

NEOVAX  INC. 

Signature of Representative, Interim President

Purchase Agreement R1

Page 1 of 13

SCHEDULE A

DESCRIPTION OF TECHNOLOGY

OVERVIEW

NeoVax Inc. is biotechnology company dedicated to developing vaccines for several infectious diseases including H5N1 influenza virus.NeoVax utilizes state of the art recombinant DNA adenoviral vector and Rnai (inhibition RNA) technologies to develop highly specific genetic vaccines. This technology platform, allows the developing of “ad hoc” genetic vaccine in a fraction of the time needed to develop conventional immunogenetic vaccines. Over the last fifty years very little progress have been made to develop faster and more effective vaccines. Large pharmaceutical companies have chosen to terminate their vaccine programs due to the high cost and minor profit margin associated with the production of vaccines. As a result vaccine R&D spending has decreased dramatically. Over the last couple of years the acute shortage of influenza vaccine coupled with the raising of new and potentially very lethal viral strains(avian influenza H5N1) has made the need of developing better and faster vaccine technologies an issue of paramount importance. NeoVax goal is to apply UltraVaxTM technology to develop highly specific DNA vaccine by targeting specific key genes for the avian influenza H5N1. Production of these recombinant vaccine can be scale up between 2-4 months compared to the current vaccine technology requiring 18-24 months.  .

This is the niche market opportunity for a platform technology firm such as 

NeoVax  to support Research and Development and Product Development. 

The 1918 influenza pandemic killed more people (about 50 million) than did the fighting in World War I. The genetic makeup of the 1918 pandemic strain (H5N1) and the reason for this virus’ extremely potent virulence have been recently elucidated and characterized. The avian flu has been touted as “Threat worse then Terror” (Newsweek, 10/31/’05). Because the flu virus has the capacity to jump from one animal species to the other, it’s a war that never ends. 

The US  have  allocated 7.1 billions in order to combat and prevent the outbreak of a flu pandemic. Epidemiologist agrees that a flu pandemic is inevitable sooner or later, although there is no way to predict if the H5N1 will be the germ to cause it. The best weapon against H5N1 or any flu virus strain would be a vaccine. The traditional “seasonal” flu vaccine development and manufacturing (via chicken egg incubation) required for about 16-18 months. In order to combat a pandemic, we need the ability to isolate the virus and convert into a vaccine and produce enough vaccine for 30 million people and we must turn it around within 8-10 months. Neovax’s adenovirus technology can speed the process by utilizing recombinant DNA technology and growing vaccines in cell cultures to cope with a fast-moving natural disaster

 

  

TECHNOLOGY

NEOVAX’s Therapeutic Strategy Against Avian Flu

Gene Expression Systems 

In addition to choosing a relevant therapeutic gene and the appropriate gene delivery system, the ability to express (turn on) the delivered gene is a key factor in the development of successful gene therapies. Current approaches utilize a variety of DNA sequences,promoters,that act as on/off switches for gene expression. Some promoters are active only in specific cell types, and are used to target gene activity to specific cells. Other promoters are expressed in a wide variety of cell types and may be used when cell-specific expression is not required. Promoter selection also depends on the level of gene expression that is desired. Inducible promoter systems which can be turned on or off in response to certain drugs or compounds are being investigated, The same is also true for self-regulating expression systems that provide very high levels of expression. The variety of gene expression systems available and under development expands the potential applications of gene therapy to new indications. 

As the genetic and molecular basis for a multiplicity of diseases is elucidated, the promise of gene therapy continues to grow. Although initial efforts in gene therapy focused on delivering a normal copy of a missing or defective gene, current programs are applying gene delivery technology across a broader spectrum of disease conditions. Gene delivery is now being used to: 

·

Replace missing or defective genes or produce recombinant proteins that exhibit therapeutic potential

·

Deliver genes that catalyze the destruction of cancer cells or cause cancer cells to revert back to normal tissue 

·

Deliver viral or bacterial genes as a form of vaccination 

·

Deliver genes that promote the growth of new tissue or stimulate regeneration of damaged tissue 

 A process for producing on a large scale highly purified Adenovirus recombinant vectors with high viral titer is applied to the production of highly purified Ad viruses carrying the specific RNA sequences for the neuroamidase and the hemoagglutinine genes.  This technology will allow NEOVAX, Inc. to develop a highly efficient avian influenza adenovirus based recombinant DNA vaccine The core platform technology is based on 1) therapeutic gene isolation, (therapeutic protein) epitope identification, and vector construction; 2) production and purification process development of therapeutic proteins, DNA and viral vectors; 3) bulk drug substance pilot-scale production; 4) quality assurance and control.

A prototype vaccine system can be developed within an 8 to 10 month period.

Purchase Agreement R1

Page 2 of 13ex4_1_117

------------------------------------------------------------------------------

                           ONE HUNDRED SEVENTEENTH
                            SUPPLEMENTAL INDENTURE

                      Southern California Edison Company

                                      to

               The Bank of New York Mellon Trust Company, N.A.

                                     and

                                D. G. Donovan,

                                   Trustees

                         DATED AS OF OCTOBER 9, 2008

------------------------------------------------------------------------------

Page 1

            This One Hundred Seventeenth Supplemental Indenture, dated as of
the 9th day of October, 2008, is entered into by and between Southern
California Edison Company (between 1930 and 1947 named "Southern California
Edison Company Ltd."), a corporation duly organized and existing under and by
virtue of the laws of the State of California and having its principal office
and mailing address at 2244 Walnut Grove Avenue, in the City of Rosemead,
County of Los Angeles, State of California 91770, and qualified to do
business in the States of Arizona, New Mexico, and Nevada (hereinafter
sometimes termed the "Company"), and The Bank of New York Mellon Trust
Company, N.A., a national banking association having its mailing address at 2
North LaSalle Street, in the City of Chicago, State of Illinois 60602
(formerly named The Bank of New York Trust Company, N.A., successor Trustee
to The Bank of New York, which was successor Trustee to Harris Trust and
Savings Bank), and D. G. Donovan of 2 North LaSalle Street, in the City of
Chicago, State of Illinois 60602 (successor Trustee to R. G. Mason, who was
successor Trustee to Wells Fargo Bank, National Association, which was
successor Trustee to Security Pacific National Bank, formerly named Security
First National Bank and Security-First National Bank of Los Angeles,
successor, by consolidation and merger, to Pacific-Southwest Trust & Savings
Bank), as Trustees (hereinafter sometimes termed the "Trustees");

            WITNESSETH:

            WHEREAS, the Company heretofore executed and delivered to said
Harris Trust and Savings Bank and said Pacific-Southwest Trust & Savings
Bank, Trustees, a certain Indenture of Mortgage or Deed of Trust dated as of
October 1, 1923, which said Indenture was duly filed for record and recorded
in the offices of the respective recorders of the following counties:  in the
State of California-Fresno County, Volume 397 of Official Records, page 1;
Imperial County, Book 1174 of Official Records, page 966; Inyo County, Volume
154 of Official Records, page 417; Kern County, Book 379 of Trust Deeds,
page 196; Kings County, Volume 84 of Deeds, page 1; Los Angeles County, Book
2963 of Official Records, page 1; Madera County, Volume 9 of Official
Records, page 63; Merced County, Volume 363 of Official Records, page 1;
Modoc County, Volume 230 of Official Records, page 119 et seq.; Mono County,
Volume 64 of Official Records, page 29; Orange County, Book 496 of Deeds,
page 1; Riverside County, Book 594 of Deeds, page 252; San Bernardino County,
Book 825 of Deeds, page 1; San Diego County, Series 5 Book 1964, page 84061;
Santa Barbara County, Book 229 of Deeds, page 30; Stanislaus County, Volume
465 of Official Records, page 370; Tulare County, Volume 50 of Official
Records, page 1; Tuolumne County, Volume 274 of Official Records, page 568;
and Ventura County, Volume 33 of Official Records, page 1; in the State of
Nevada-Clark County, Book 8 of Mortgages; Churchill County, Book 40 of
Official Records, page 235; Lyon County, Book 39 of Mortgages, page 1;
Mineral County, Book 13 of Official Records, page 794; Pershing County, Book
15 of Official Records, page 612; and Washoe County, Book 83 of Mortgages,
page 301; in the State of Arizona-La Paz County, Instrument No. 83-000212 of
Official Records; Mohave County, Book 11 of Realty Mortgages; Maricopa
County, Docket 4349 of Official Records, page 197; and Yuma County, Docket
369, page 310; and in the offices of the county clerks of the following
counties in the State of New Mexico-McKinley County, Book Mtg. 50, page 187
and filed as Document No. 10536 in the Chattel Records; and San Juan County,
Book Mtg. 630, page 13 and filed as Document No. 17838 in the Chattel Records
(hereinafter referred to as the "Original Indenture"), to secure the payment
of the principal of and interest on all bonds of the Company at any time
outstanding thereunder, and (as to certain such filings or recordings) the
principal of and interest on all Debentures of 1919 (referred to in the
Original Indenture and now retired) outstanding; and

            WHEREAS, the Company has heretofore executed and delivered to the
Trustees one hundred sixteen certain supplemental indentures, dated,
respectively, as of March 1, 1927, April 25, 1935, June 24, 1935,
September 1, 1935, August 15, 1939, September 1, 1940, January 15, 1948,
August 15, 1948, February 15, 1951, August 15, 1951, August 15, 1953,
August 15, 1954, April 15, 1956, February 15, 1957, July 1, 1957, August 15,
1957, August 15, 1958, January 15, 1960, August 15, 1960, April 1, 1961, May
1, 1962, October 15, 1962, May 15, 1963, February 15, 1964, February 1, 1965,
May 1, 1966, August 15, 1966, May 1, 1967, February 1, 1968, January 15,
1969, October 1, 1969, December 1, 1970, September 15, 1971, August 15, 1972,
February 1, 1974, July 1, 1974, November 1, 1974, March 1, 1975, March 15,
1976, July 1, 1977, November 1, 1978, June 15, 1979, September 15, 1979,
October 1, 1979, April 1, 1980, November 15, 1980, May 15, 1981, August 1,
1981, December 1, 1981, January 16, 1982, April 15, 1982, November 1, 1982,
November 1, 1982, January 1, 1983, May 1, 1983, December 1, 1984,

Page 2

March 15,
1985, October 1, 1985, October 15, 1985, March 1, 1986, March 15, 1986, April
15, 1986, April 15, 1986, July 1, 1986, September 1, 1986, September 1, 1986,
December 1, 1986, July 1, 1987, October 15, 1987, November 1, 1987, February
15, 1988, April 15, 1988, July 1, 1988, August 15, 1988, September 15, 1988,
January 15, 1989, May 1, 1990, June 15, 1990, August 15, 1990, December 1,
1990, April 1, 1991, May 1, 1991, June 1, 1991, December 1, 1991, February 1,
1992, April 1, 1992, July 1, 1992, July 15, 1992, December 1, 1992, January
15, 1993, March 1, 1993, June 1, 1993, June 15, 1993, July 15, 1993,
September 1, 1993, October 1, 1993, February 21, 2002, February 15, 2003,
October 15, 2003, December 15, 2003, January 7, 2004, February 26, 2004,
March 23, 2004, December 6, 2004, January 11, 2005, January 27, 2005, March
17, 2005, June 1, 2005, June 20, 2005, August 24, 2005, December 12, 2005,
January 24, 2006, April 4, 2006, December 4, 2006, January 14, 2008, and
August 13, 2008, which modify, amend and supplement the Original Indenture,
such Original Indenture, as so modified, amended and supplemented, being
hereinafter referred to as the "Amended Indenture"; and

            WHEREAS, there have been issued and are now outstanding and
entitled to the benefits of the Amended Indenture, First and Refunding
Mortgage Bonds as follows:

         Series             Due Date          Principal Amount
         2004A                2014                 300,000,000
         2004B                2034                 525,000,000
         2004D                2035                  79,400,000
         2004E                2035                  65,000,000
         2004F                2015                 300,000,000
         2004G                2035                 350,000,000
         2005A                2016                 400,000,000
         2005B                2036                 250,000,000
         2005D                2029                 203,460,000
         2005E                2035                 350,000,000
         2005F                2035                 248,585,000
         2006A                2036                 350,000,000
         2006B                2009                 150,000,000
         2006C                2028                 196,000,000
         2006D                2033                 135,000,000
         2006E                2037                 400,000,000
         2008A                2038                 600,000,000
         2008B                2018                 400,000,000

            WHEREAS, the Company proposes presently to issue in fully
registered form only, without coupons, up to $500,000,000 aggregate principal
amount of a new series of the Company's First and Refunding Mortgage Bonds,
pursuant to resolutions of the Board of Directors or the Executive Committee
of the Board of Directors of the Company, or actions by one or more officers
of the Company, said new series to be designated as Series 2008C and Series
2008D (referred to herein as the "Bond"), and the Company's authorized bonded
indebtedness has been increased to provide for the issuance of the Bond; and

            WHEREAS, the Company has acquired real and personal property
since the execution and delivery of the One Hundred Fifteenth Supplemental
Indenture which, with certain exceptions, is subject to the lien of the
Amended Indenture by virtue of the after-acquired property clauses and other
clauses thereof, and the Company now desires in this One Hundred Seventeenth
Supplemental Indenture (hereinafter sometimes referred to as this
"Supplemental Indenture") expressly to convey and confirm unto the Trustees
all properties, whether real, personal or mixed, now owned by the Company
(with the exceptions hereinafter noted); and

            WHEREAS, for the purpose of further safeguarding the rights and
interests of the holders of bonds under the Amended Indenture, the Company
desires, in addition to such conveyance, to enter into certain covenants with
the Trustees; and

Page 3

            WHEREAS, the making, executing, acknowledging, delivering and
recording of this Supplemental Indenture have been duly authorized by proper
corporate action of the Company, and the Trustees have each duly determined
to execute and accept this Supplemental Indenture;

            NOW, THEREFORE, in order further to secure the payment of the
principal of and interest on all of the bonds of the Company at any time
outstanding under the Amended Indenture, as from time to time amended and
supplemented, including specifically, but without limitation, the First and
Refunding Mortgage Bonds, Series 2004A, Series 2004B, Series 2004D, Series
2004E, Series 2004F, Series 2004G, Series 2005A, Series 2005B, Series 2005D,
Series 2005E, Series 2005F, Series 2006A, Series 2006B, Series 2006C, Series
2006D, Series 2006E, 2008A, and 2008B, referred to above, all of said bonds
having been heretofore issued and being now outstanding, and the Bonds, of
the aggregate principal amount of up to $500,000,000, to be presently issued
and outstanding; and to secure the performance and observance of each and
every of the covenants and agreements contained in the Amended Indenture, and
without in any way limiting (except as hereinafter specifically provided) the
generality or effect of the Original Indenture or any of said supplemental
indentures executed and delivered prior to the execution and delivery of this
Supplemental Indenture insofar as by any provision of any said Indenture any
of the properties hereinafter referred to are subject to the lien and
operation thereof, but to such extent (except as hereinafter specifically
provided) confirming such lien and operation, and for and in consideration of
the premises, and of the sum of One Dollar ($1.00) to the Company duly paid
by the Trustees, at or upon the ensealing and delivery of these presents (the
receipt whereof is hereby acknowledged), the Company has executed and
delivered this Supplemental Indenture and has granted, bargained, sold,
aliened, released, conveyed, assigned, transferred, warranted, mortgaged, and
pledged, and by these presents does grant, bargain, sell, alien, release,
convey, assign, transfer, warrant, mortgage, and pledge unto the Trustees,
their successors in trust and their assigns forever, in trust, with power of
sale, all of the following:

            All and singular the plants, properties (including goods which
are or are to become fixtures), equipment, and generating, transmission,
feeding, storing, and distributing systems, and facilities and utilities of
the Company in the Counties of Fresno, Imperial, Inyo, Kern, Kings, Los
Angeles, Madera, Merced, Modoc, Mono, Orange, Riverside, San Bernardino, San
Diego, Santa Barbara, Stanislaus, Tulare, Tuolumne, and Ventura, in the State
of California, Churchill, Clark, Lyon, Mineral, Pershing, and Washoe, in the
State of Nevada, La Paz and Maricopa, in the State of Arizona, and McKinley
and San Juan, in the State of New Mexico, and elsewhere either within or
without said States, with all and singular the franchises, ordinances,
grants, easements, rights-of-way, permits, privileges, contracts,
appurtenances, tenements, and other rights and property thereunto
appertaining or belonging, as the same now exist and as the same or any and
all parts thereof may hereafter exist or be improved, added to, enlarged,
extended or acquired in said Counties, or elsewhere either within or without
said States;

            Together with, to the extent permitted by law, all other
properties, real, personal, and mixed (including goods which are or are to
become fixtures), except as herein expressly excepted, of every kind, nature,
and description, including those kinds and classes of property described or
referred to (whether specifically or generally or otherwise) in the Original
Indenture and/or in any one or more of the indentures supplemental thereto,
now or hereafter owned, possessed, acquired or enjoyed by or in any manner
appertaining to the Company, and the reversion and reversions, remainder and
remainders, tolls, incomes, revenues, rents, issues, and profits thereof; it
being hereby intended and expressly agreed that all the business, franchises,
and properties, real, personal, and mixed (except as herein expressly
excepted), of every kind and nature whatsoever and wherever situated, now
owned, possessed, or enjoyed, and which may hereafter be in anywise owned,
possessed, acquired, or enjoyed by the Company, shall be as fully embraced
within the provisions hereof and be subject to the lien created hereby and by
the Original Indenture and said supplemental indentures executed and
delivered prior to the execution and delivery of this Supplemental Indenture,
as if said properties were particularly described herein;

            Saving and excepting, however, anything contained herein or in
the granting clauses of the Original Indenture, or of the above mentioned
indentures supplemental thereto, or elsewhere contained in

Page 4

the Original
Indenture or said supplemental indentures, to the contrary notwithstanding,
from the property hereby or thereby mortgaged and pledged, all of the
following property (whether now owned by the Company or hereafter acquired by
it):  all bills, notes, warrants, customers' service and extension deposits,
accounts receivable, cash on hand or deposited in banks or with any
governmental agency, contracts, choses in action, operating agreements and
leases to others (as distinct from the property leased and without limiting
any rights of the Trustees with respect thereto under any of the provisions
of the Amended Indenture), all bonds, obligations, evidences of indebtedness,
shares of stock and other securities, and certificates or evidences of
interest therein, all office furniture and office equipment, motor vehicles
and tools therefor, all materials, goods, merchandise, and supplies acquired
for the purpose of sale in the ordinary course of business or for consumption
in the operation of any property of the Company, and all electrical energy
and other materials or products produced by the Company for sale,
distribution, or use in the ordinary conduct of its business--other than any
of the foregoing which has been or may be specifically transferred or
assigned to or pledged or deposited with the Trustees, or any of them, under
the Amended Indenture, or required by the provisions of the Amended
Indenture, so to be; provided, however, that if, upon the occurrence of a
default under the Amended Indenture, the Trustees, or any of them, or any
receiver appointed under the Amended Indenture, shall enter upon and take
possession of the mortgaged and pledged property, the Trustees, or such
Trustee or such receiver may, to the extent permitted by law, at the same
time likewise take possession of any and all of the property excepted by this
paragraph then on hand which is used or useful in connection with the
business of the Company, and collect, impound, use, and administer the same
to the same extent as if such property were part of the mortgaged and pledged
property and had been specifically mortgaged and pledged hereunder, unless
and until such default shall be remedied or waived and possession of the
mortgaged and pledged property restored to the Company, its successors or
assigns, and provided further, that upon the taking of such possession and
until possession shall be restored as aforesaid, all such excepted property
of which the Trustees, or such Trustee or such receiver shall have so taken
possession, shall be and become subject to the lien hereof, subject, however,
to any liens then existing on such excepted property.

            And the Company does hereby covenant and agree with the Trustees,
and the Trustees with the Company, as follows:

                                    PART I

            The Trustees shall have and hold all and singular the properties
conveyed, assigned, mortgaged and pledged hereby or by the Amended Indenture,
including property hereafter as well as heretofore acquired, in trust for the
equal and proportionate benefit and security of all present and future
holders of the bonds and interest obligations issued and to be issued under
the Amended Indenture, as from time to time amended and supplemented, without
preference of any bond over any other bond by reason of priority in date of
issuance, negotiation, time of maturity, or for any other cause whatsoever,
except as otherwise in the Amended Indenture, as from time to time amended
and supplemented, permitted, and to secure the payment of all bonds now or at
any time hereafter outstanding under the Amended Indenture, as from time to
time amended and supplemented, and the performance of and compliance with the
covenants and conditions of the Amended Indenture, as from time to time
amended and supplemented, and under and subject to the provisions and
conditions and for the uses set forth in the Amended Indenture, as from time
to time amended and supplemented.

                                   PART II

            Article I to Article Twenty-One, inclusive, of the Amended
Indenture are hereby incorporated by reference herein and made a part hereof
as fully as though set forth at length herein.

                                   PART III

            All of the terms appearing herein shall be defined as the same
are now defined under the provisions of the Amended Indenture, except when
expressly herein otherwise defined.

Page 5

                                   PART IV

            Pursuant to Section 1 of Article Five of the Original Indenture,
as amended by Part IV, Subpart C, of the Sixth Supplemental Indenture, dated
as of September 1, 1940, the notice to be given with respect to the
redemption of the Bonds in whole or in part, shall be limited to and shall
consist of the giving by the Company or The Bank of New York Mellon Trust
Company, N.A., Trustee, of a notice in writing (including by facsimile
transmission) of such redemption, at least 30 days, but not more than 60
days, prior to the date fixed for redemption to the holder of each Bond
called for redemption at the holder's last address shown on the registry
books of the Company.  Failure to so provide such notice to the holder of any
Bond shall not affect the validity of the redemption proceedings with respect
to any other Bond.

                                    PART V

            The Bonds shall be in substantially the form set forth in a
resolution of the Board of Directors or the Executive Committee of the Board
of Directors of the Company, or a certificate evidencing action by an officer
or officers of the Company, and may have placed thereon such letters, numbers
or other marks of identification and such legends or endorsements as set
forth in this Supplemental Indenture or as may be required to comply with the
Securities Act of 1933, as amended (the "Securities Act"), any other laws,
any other rules of the Securities and Exchange Commission or any securities
exchange, or as may, consistently herewith, be determined to be necessary or
appropriate by the officers executing the Bonds, as evidenced by their
execution of the Bonds.

            The Bonds initially shall be represented by one or more
securities in registered, global form without interest coupons ("Global
Bonds").  Each certificate for Global Bonds shall represent the aggregate
principal of outstanding Bonds from time to time endorsed thereon and the
aggregate principal amount of outstanding Bonds represented thereby may from
time to time be reduced or increased, as appropriate, to reflect exchanges
and redemptions.  Any endorsement of a Global Bond certificate to reflect the
amount of any increase or decrease in the aggregate principal amount of
outstanding Bonds represented thereby shall be made by The Bank of New York
Mellon Trust Company, N.A., Trustee, as registrar for the Bonds (the "Bond
Registrar"), in accordance with instructions given by the registered holder
thereof.

            The Company initially appoints The Depository Trust Company
("DTC") to act as depositary with respect to the Global Bonds (together with
any successor, the "Depositary").  Each certificate representing Global Bonds
shall bear a legend in substantially the following form (the "Global Bond
Legend"):

            UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED
            REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK
            CORPORATION ("DTC"), TO SOUTHERN CALIFORNIA EDISON COMPANY OR ITS
            AGENT FOR REGISTRATION OR TRANSFER, EXCHANGE, OR PAYMENT, AND ANY
            CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN
            SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
            OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER
            ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC),
            ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE
            BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
            HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

            Beneficial interests in the Global Bonds may not be exchanged for
Bonds in certificated form ("Certificated Bonds") except in the limited
circumstances set forth below in this Supplemental Indenture.  Certificates
representing Certificated Bonds will not bear the Global Bond Legend.

Page 6

                                   PART VI

            The transfer and exchange of Global Bonds or beneficial interests
in Global Bonds shall be effected through the Depositary, in accordance with
the terms of the Amended Indenture (including the restriction on transfer set
forth herein) and the procedures of the Depositary.

            A Global Bond may be exchanged for Certificated Bonds if (a) the
Depositary for the Global Bond notifies the Company that the Depositary is
unwilling or unable to continue as to act as Depositary for the Global Bond
or has ceased to be a clearing agency registered under the Securities
Exchange Act of 1934, and in either case the Company fails to appoint a
successor Depositary within 90 days after delivery of such notice; (b) the
Company notifies the Bond Registrar in writing that it has elected to cause
the issuance of Certificated Bonds; or (c) there has occurred and is
continuing a default with respect to the Bonds under the Amended Indenture.
Certificated Bonds delivered in exchange for any Global Bond or beneficial
interests in Global Bonds will be executed by the Company, authenticated by
The Bank of New York Mellon Trust Company, N.A., as Trustee, registered in
the names, and issued in any approved denominations, requested by or on
behalf of the Depositary (in accordance with its customary procedures).

            When Certificated Bonds are presented to the Bond Registrar with
a request to register the transfer of the Certificated Bonds or to exchange
such Certificated Bonds for an equal principal amount of Certificated Bonds
of other authorized denominations, the Bond Registrar shall register the
transfer or make the exchange as requested if its requirements for such
transactions are met.

                                   PART VII

            All, but only, the duties, responsibilities, liabilities,
immunities, rights, powers, and indemnities against liability, of the
Trustees and each of them, with respect to the trust created by the Amended
Indenture, are hereby assumed by and given to the Trustees, and each of them,
with respect to the trust hereby created, and are so assumed and given
subject to all the terms and provisions with respect thereto as set forth in
the Amended Indenture, as fully and to all intents and purposes as if the
same were herein set forth at length; and this Supplemental Indenture is
executed by the Trustees for the purpose of evidencing their consent to the
foregoing.

            The recitals contained herein, except the recital that the
Trustees have each duly determined to execute and deliver this Supplemental
Indenture, shall be taken as the statements of the Company, and the Trustees
assume no responsibility for the correctness thereof.  The Trustees make no
representations as to the validity of this Supplemental Indenture.

                                  PART VIII

            As amended and supplemented by this Supplemental Indenture, the
Amended Indenture is in all respects ratified and confirmed, and the Original
Indenture and all said indentures supplemental thereto including this
Supplemental Indenture, shall be read, taken, and considered as one
instrument, and the Company agrees to conform to and comply with all and
singular the terms, provisions, covenants, and conditions set forth therein
and herein.

                                   PART IX

            In case any one or more of the provisions contained in this
Supplemental Indenture should be invalid, illegal, or unenforceable in any
respect, such invalidity, illegality, or unenforceability shall not affect
any other provisions contained in this Supplemental Indenture, and, to the
extent and only to the extent that any such provision is invalid, illegal, or
unenforceable, this Supplemental Indenture shall be construed as if such
provision had never been contained herein.

Page 7

                                    PART X

            This Supplemental Indenture may be simultaneously executed and
delivered in any number of counterparts, each of which, when so executed and
delivered, shall be deemed to be an original.

Page 8

            IN WITNESS WHEREOF, the Company has caused its corporate name and
seal to be hereunto affixed and this Supplemental Indenture to be signed by
its Chairman of the Board, its Chief Executive Officer, its President, or one
of its Vice Presidents and attested by the signature of its Secretary or one
of its Assistant Secretaries, for and in its behalf; said The Bank of New
York Mellon Trust Company, N.A. has caused its name to be hereunto affixed,
and this Supplemental Indenture to be signed, by one of its Vice Presidents
or Assistant Vice Presidents or Agents; and said D. G. Donovan has hereunto
executed this Supplemental Indenture; all as of the day and year first above
written.  Executed in counterparts and in multiple.

                                          SOUTHERN CALIFORNIA EDISON COMPANY

                                          /s/ ROBERT C. BOADA
                                          ---------------------------------------
                                          ROBERT C. BOADA
                                          Vice President and Treasurer

Attest:

/s/ BONITA J. SMITH
----------------------------------------------------
BONITA J. SMITH
Assistant Secretary

(Seal)

                                          THE BANK OF NEW YORK MELLON TRUST
                                          COMPANY, N.A., Trustee

                                          /s/ JUDITH L. BARTOLINI
                                          ---------------------------------------
                                          Name:  JUDITH L. BARTOLINI
                                          Title:  Vice President

                                          /s/ D. G. DONOVAN
                                          ---------------------------------------
                                          D. G. DONOVAN
                                          Trustee

Page 9

STATE OF CALIFORNIA     }
                        }  ss.
COUNTY OF LOS ANGELES   }

      On this 9th day of October, 2008, before me, SARAH C. PEREZ, a Notary
Public, personally appeared ROBERT C. BOADA and BONITA J. SMITH, who proved
to me on the basis of satisfactory evidence to be the persons whose names are
subscribed to the within instrument and acknowledged to me that they executed
the same in their authorized capacities, and that by their signatures on the
instrument the persons, or the entity on behalf of which the persons acted,
executed the instrument.

      I  certify  under  PENALTY  OF  PERJURY  under  the laws of the State of
California that the foregoing paragraph is true and correct.

      WITNESS my hand and official seal.

                                          /s/ SARAH C. PEREZ
                                          ---------------------------------------
                                          Notary Public, State of California

(Seal)

My Commission expires on August 22, 2009.

Page 10

STATE OF ILLINOIS   }
                    }  ss.
COUNTY OF COOK      }

      On this 9th day of October, 2008, before me, T. MOSTERD, a Notary
Public, personally appeared Judith L. Bartolini, Vice President of THE BANK
OF NEW YORK MELLON TRUST COMPANY, N.A., Trustee, who proved to me on the
basis of satisfactory evidence to be the person whose name is subscribed to
the within instrument and acknowledged to me that she executed the same in
her authorized capacity, and that by her signature on the instrument the
person, or entity on behalf of which the person acted, executed the
instrument.

      WITNESS my hand and official seal.

                                          /s/ T. MOSTERD
                                          ---------------------------------------
                                          Notary Public

(Seal)

My Commission expires on January 22, 2009.

STATE OF ILLINOIS }
                  }  ss.
COUNTY OF COOK    }

      On this 9th day of October, 2008, before me, T. MOSTERD, a Notary
Public, personally appeared D. G. DONOVAN, Trustee, who proved to me on the
basis of satisfactory evidence to be the person whose name is subscribed to
the within instrument and acknowledged to me that he executed the same in his
authorized capacity, and that by his signature on the instrument the person,
or entity on behalf of which the person acted, executed the instrument.

      WITNESS my hand and official seal.

                                          /s/ T. MOSTERD
                                          ---------------------------------------
                                          Notary Public

(Seal)

My Commission expires on January 22, 2009.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]